LD50 information for peginterferon beta-1a is not readily available in the literature. In clinical trials, no cases of overdoses occurred with the administration of interferon beta-1a at a dose of 75 ?g administered subcutaneously 3 times a week.L31428 In a case report, a 38-year-old patient attempted suicide with about 6 or 7 pre-filled syringes containing 44 mug (12 MIU) of subcutaneous interferon beta-1a; symptoms were limited to malaise and skin erythema, which resolved within 24 hours with no intervention. Laboratory test results were unremarkable.A191871 In the case of an overdose with interferon-beta 1a, prescribing information suggests to contact the local poison control centre.L31438
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings.L5801 MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.A176474,L5792
Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021.L31428 Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Peginterferon beta-1a. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Peginterferon beta-1a. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Peginterferon beta-1a. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Peginterferon beta-1a. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Peginterferon beta-1a. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Peginterferon beta-1a. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Peginterferon beta-1a. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Peginterferon beta-1a. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Peginterferon beta-1a. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Peginterferon beta-1a. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Peginterferon beta-1a. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Peginterferon beta-1a. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Peginterferon beta-1a. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Peginterferon beta-1a. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Peginterferon beta-1a. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Peginterferon beta-1a. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Peginterferon beta-1a. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Peginterferon beta-1a. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Peginterferon beta-1a. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Peginterferon beta-1a. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Peginterferon beta-1a. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Peginterferon beta-1a. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Peginterferon beta-1a. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Peginterferon beta-1a. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Peginterferon beta-1a. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Peginterferon beta-1a. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Peginterferon beta-1a. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Peginterferon beta-1a. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Peginterferon beta-1a. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Peginterferon beta-1a. |
| Cladribine | Peginterferon beta-1a may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Peginterferon beta-1a. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Peginterferon beta-1a. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Peginterferon beta-1a. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Peginterferon beta-1a. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Peginterferon beta-1a. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Peginterferon beta-1a. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Peginterferon beta-1a. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Peginterferon beta-1a. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Peginterferon beta-1a. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Peginterferon beta-1a. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Peginterferon beta-1a. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Peginterferon beta-1a. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Peginterferon beta-1a. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Peginterferon beta-1a. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Peginterferon beta-1a. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Peginterferon beta-1a. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Peginterferon beta-1a. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Peginterferon beta-1a. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Peginterferon beta-1a. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Peginterferon beta-1a. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Peginterferon beta-1a. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Peginterferon beta-1a. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Peginterferon beta-1a. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Peginterferon beta-1a. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Peginterferon beta-1a. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Peginterferon beta-1a. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Peginterferon beta-1a. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Peginterferon beta-1a. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Peginterferon beta-1a. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Peginterferon beta-1a. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Peginterferon beta-1a. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Peginterferon beta-1a. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Peginterferon beta-1a. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Peginterferon beta-1a. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Peginterferon beta-1a. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Peginterferon beta-1a. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Peginterferon beta-1a. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Peginterferon beta-1a. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Peginterferon beta-1a. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Peginterferon beta-1a. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Peginterferon beta-1a. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Peginterferon beta-1a. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Peginterferon beta-1a. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Peginterferon beta-1a. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Peginterferon beta-1a. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Peginterferon beta-1a. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Peginterferon beta-1a. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Peginterferon beta-1a. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Peginterferon beta-1a. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Peginterferon beta-1a. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Peginterferon beta-1a. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Peginterferon beta-1a. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Peginterferon beta-1a. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Peginterferon beta-1a. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Peginterferon beta-1a. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Peginterferon beta-1a. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Peginterferon beta-1a. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Peginterferon beta-1a. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Peginterferon beta-1a. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Peginterferon beta-1a. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Peginterferon beta-1a. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Peginterferon beta-1a. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Doxorubicin is combined with Peginterferon beta-1a. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Peginterferon beta-1a. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Peginterferon beta-1a. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Peginterferon beta-1a. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Peginterferon beta-1a. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Peginterferon beta-1a. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Peginterferon beta-1a. |